Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study

Fig. 2

a CNS time to progression in three cohorts. With a median follow-up of 19.2 months, 22.5 months, and 15.8 months in these three cohorts respectively, CNS TTP was NE vs 33.0 m vs NE. b Intracranial duration of response in three cohorts. With median follow-up of 18.7 months, 22.7 months, and 16.8 months in these three cohorts respectively, ic-DOR was NE vs NE vs NE. c CNS TTP in patients with uncontrolled CNS metastases. With a median follow-up of 19.0 months, 22.6 months, and 12.3 months in these three cohorts respectively, CNS TTP was NE vs 33.0 m vs NE

Back to article page